泓博医药
(301230)
| 流通市值：22.70亿 | | | 总市值：41.23亿 |
| 流通股本：7686.03万 | | | 总股本：1.40亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 80,859,628.03 | 84,519,980.92 | 93,011,587.84 | 124,784,163.71 |
| 应收票据及应收账款 | 133,614,121.99 | 99,754,124.56 | 110,820,215.44 | 112,525,231.54 |
| 其中：应收票据 | 9,312,016.35 | 1,108,865.2 | 1,081,641.5 | 1,216,185.25 |
| 应收账款 | 124,302,105.64 | 98,645,259.36 | 109,738,573.94 | 111,309,046.29 |
| 应收款项融资 | 1,868,206.51 | 2,031,034.2 | - | 3,643,973.56 |
| 预付款项 | 3,803,341.37 | 2,432,106.86 | 4,331,673.19 | 3,241,973.72 |
| 其他应收款合计 | 4,529,490.98 | 4,561,479.77 | 25,418,956.03 | 5,875,244.24 |
| 存货 | 67,987,059.69 | 69,043,072.78 | 77,489,533.84 | 72,645,240.16 |
| 其他流动资产 | 38,287,922.11 | 40,206,823.62 | 39,383,020.45 | 39,928,874.34 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 584,490,479.58 | 554,317,975.45 | 620,478,092.95 | 670,518,249.22 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 20,081,264 | 20,081,390 | 11,855,486 | 11,981,450.84 |
| 固定资产 | 194,520,877.08 | 199,001,574.93 | 187,362,294.39 | 180,311,589.55 |
| 在建工程 | 1,161,104.47 | 1,423,850.01 | 8,838,465.74 | 100,935,865.31 |
| 使用权资产 | 153,678,002.5 | 159,405,055 | 165,132,107.5 | 170,859,160 |
| 无形资产 | 8,450,305.57 | 8,489,297.45 | 8,397,221.12 | 8,483,400.33 |
| 长期待摊费用 | 309,464,856.77 | 318,971,675.65 | 328,417,326.95 | 246,668,736.2 |
| 递延所得税资产 | 34,952,819.44 | 30,806,077.06 | 24,967,147.83 | 19,955,185.03 |
| 其他非流动资产 | 24,470,316.17 | 23,929,492.64 | 2,713,007.07 | 1,466,629.2 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 746,779,546 | 762,108,412.74 | 737,683,056.6 | 740,662,016.46 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,331,270,025.58 | 1,316,426,388.19 | 1,358,161,149.55 | 1,411,180,265.68 |
| 流动负债: | | | | |
| 短期借款 | 17,664,171.34 | 10,011,000 | 12,326,751.4 | 19,666,670.89 |
| 应付票据及应付账款 | 50,852,520.82 | 52,121,784.11 | 76,491,612.68 | 104,674,778.09 |
| 其中：应付票据 | - | 5,227,213.77 | 5,227,213.77 | 2,100,000 |
| 应付账款 | 50,852,520.82 | 46,894,570.34 | 71,264,398.91 | 102,574,778.09 |
| 预收款项 | 1,917,004.64 | 1,981,437.78 | 1,955,247.78 | 1,955,115.49 |
| 合同负债 | 4,713,880.87 | 3,123,859.02 | 5,154,241.03 | 2,182,279.14 |
| 应付职工薪酬 | 22,184,887.16 | 30,913,716.62 | 27,792,807.89 | 24,403,050.48 |
| 应交税费 | 3,184,114.01 | 2,271,791.9 | 2,375,716.61 | 4,422,676.87 |
| 其他应付款合计 | 2,866,427.51 | 3,359,665.37 | 3,033,739.09 | 3,090,290.1 |
| 一年内到期的非流动负债 | 21,839,432.12 | 20,405,967.38 | 20,158,021.91 | 19,913,089.13 |
| 其他流动负债 | 8,869,062.98 | 1,208,298.39 | 1,368,308.92 | 1,371,399.5 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 134,091,501.45 | 125,397,520.57 | 150,656,447.31 | 181,679,349.69 |
| 非流动负债: | | | | |
| 租赁负债 | 146,029,844.31 | 151,289,166.82 | 156,484,585.23 | 161,616,876.04 |
| 预计负债 | 1,137,097.58 | 3,568,004.9 | 3,181,464.79 | 2,235,350.61 |
| 递延收益 | 245,610.52 | 168,010.52 | 80,000 | - |
| 递延所得税负债 | 3,521,754.85 | 3,306,227.58 | 3,210,844.03 | 2,692,083.42 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 150,934,307.26 | 158,331,409.82 | 162,956,894.05 | 166,544,310.07 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 285,025,808.71 | 283,728,930.39 | 313,613,341.36 | 348,223,659.76 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 139,586,605 | 139,586,605 | 139,586,605 | 139,586,605 |
| 资本公积 | 768,464,183.39 | 766,810,139.45 | 766,810,139.45 | 766,810,139.45 |
| 减:库存股 | 53,080,912.43 | 53,080,912.43 | 53,075,305.42 | 35,352,317.52 |
| 其他综合收益 | -16,235.54 | 64,923.15 | -4,824.99 | -51,900.47 |
| 盈余公积 | 29,841,348.57 | 29,841,348.57 | 24,852,529.51 | 24,852,529.51 |
| 未分配利润 | 161,449,227.88 | 149,475,354.06 | 166,378,664.64 | 167,111,549.95 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,046,244,216.87 | 1,032,697,457.8 | 1,044,547,808.19 | 1,062,956,605.92 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,046,244,216.87 | 1,032,697,457.8 | 1,044,547,808.19 | 1,062,956,605.92 |
| 负债和股东权益合计 | 1,331,270,025.58 | 1,316,426,388.19 | 1,358,161,149.55 | 1,411,180,265.68 |
| 公告日期 | 2025-04-29 | 2025-04-24 | 2024-10-28 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |